We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Silver linings plague-book

18 Mar 2020 By Christopher Thompson

Elliott dropped its resistance to French IT firm Capgemini’s $4.1 bln bid for Altran. Tendering shares is an awkward U-turn after complaining the offer undervalued its target. But cash talks. In walking away, the activist U.S. fund crystallises a rare gain in a crashing market.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)